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ABSTRACT
Epithelial to mesenchymal transition (EMT) induces cell plasticity and promotes 
metastasis. The multifunctional oncoprotein Y-box binding protein-1 (YB-1) and the 
pleiotropic cytokine interleukin 6 (IL-6) have both been implicated in tumor cell 
metastasis and EMT, but via distinct pathways. Here, we show that direct interplay 
between YB-1 and IL-6 regulates breast cancer metastasis. Overexpression of YB-1 in 
breast cancer cell lines induced IL-6 production while stimulation with IL-6 increased 
YB-1 expression and YB-1 phosphorylation. Either approach was sufficient to induce 
EMT features, including increased cell migration and invasion. Silencing of YB-1 
partially reverted the EMT and blocked the effect of IL-6 while inhibition of IL-6 
signaling blocked the phenotype induced by YB-1 overexpression, demonstrating a 
clear YB-1/IL-6 interdependence. Our findings describe a novel signaling network 
in which YB-1 regulates IL-6, and vice versa, creating a positive feed-forward loop 
driving EMT-like metastatic features during breast cancer progression. Identification 
of signaling partners or pathways underlying this co-dependence may uncover novel 
therapeutic opportunities.
INTRODUCTION
Despite major advances in the past 40 years, the 
inability to cure metastatic disease remains a significant 
hurdle to effective cancer therapy. It is also usually the 
underlying cause of breast cancer death. Metastasis 
is a complex process in which metastatic cancer cells 
disseminate from primary sites and invade secondary target 
organs such as the lungs, bone, and brain [1]. One step 
toward tumor progression is the epithelial to mesenchymal 
transition (EMT) [2–4]. The EMT, orchestrated by the 
upregulation of oncogenic transcription factors such as 
TWIST1/2, SNAI1/2, and ZEB1/2 facilitates the acquisition 
of mesenchymal characteristics, such as plasticity, migratory 
capacity, and invasiveness, and allows cancer cells to escape 
from the primary tumor to form distant metastasis.
Y-box binding protein 1 (YB-1) is a highly 
regulated protein with multiple localization-dependent 
functions. In the nucleus, YB-1 acts as a transcription/
splicing factor, whereas, in the cytoplasm, it binds to 
and stabilizes mRNA in order to regulate translation 
[5]. In the last decade, YB-1 has been identified as a 
principal factor in many malignant tumors [6, 7] and is 
involved in many of the “hallmarks of cancer” proposed 
by Hanahan and Weinberg [8]. Elevated YB-1 protein 
levels have been associated with poor prognosis and drug 
resistance [9], relapse [10], progression [11], induction of 
cancer stem cell-like features [12], and metastasis [13]. 
YB-1 is overexpressed in breast cancer, especially in the 
aggressive triple-negative (TNBC) subtypes, almost 70% 
of which are strongly positive for YB-1 [10]. Davies and 
coworkers [14] elegantly showed that YB-1 contributes to 
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the conversion of hormone receptor-positive breast cancer 
cells to the TNBC phenotype.
During tumor progression, the tumor 
microenvironment favors the release of proinflammatory 
cytokines. The combination of intrinsic tumor 
characteristics and diverse environmental cues can 
contribute to the metastatic process. Abnormal cytokine 
signaling plays a key role in cancer metastasis by creating 
the appropriate inflammatory microenvironment [15]. 
Of the cytokines participating in the cancer process, 
interleukin 6 (IL-6) has been shown to promote breast 
cancer metastasis [16–18], and high IL-6 levels are 
associated with poor clinical outcomes in breast tumors 
[19]. Activation of IL-6 triggers three signaling pathways: 
(i) JAK/STAT3, (ii) PI3K/AKT/mTOR, and (iii) Ras Raf/
MEK-ERK/MNK. These pathways converge in autocrine 
or paracrine phosphorylation of STAT3, making IL-6 a key 
contributor to tumor growth, drug resistance, induction of 
cancer stem cells, and metastasis [17]. Additionally, IL-6 
itself [20, 21] and components of its signaling pathway, 
including JAK/STAT3 [22], MEK1 [23], and PI3K/AKT 
[24], can induce EMT. Notably, expression of estrogen 
receptor (ER) correlates inversely with that of IL-6 [25], 
meaning that ER-negative breast cancers, including 
TNBC subtypes, produce more IL-6 than ER-positive 
tumors [26, 27] and are able to exploit both paracrine 
and autocrine IL-6 signaling. Similarly, TNBCs express 
high levels of active YB-1 [9, 28] and IL-6, whereas ER-
positive cell lines have lower levels of both proteins.
Recently, YB-1 has been shown to promote 
metastatic features such as migration, invasion, and EMT 
characteristics [29–33]. However, its interplay with other 
signaling pathways regulating EMT processes, such as 
cytokines, remains poorly studied.
In the present work, we explored the relationship 
between YB-1 and IL-6 signaling in the acquisition of 
EMT characteristics by breast cancer cells. Our results 
show that YB-1 increases cell migration and invasion, in a 
process that appears to require the concomitant induction 
of IL-6 production. Moreover, induction of EMT by 
IL-6 also requires the upregulation of YB-1. Our results 
describe a novel mechanism in which YB-1 induces 
metastatic characteristics through IL-6 expression, and 
vice versa.
RESULTS
YB-1 overexpression promotes cellular migration 
and invasion in breast cancer cells
Aggressive and metastatic breast tumors, such as 
TNBC, express high levels of YB-1 [34]. To determine 
whether YB-1 levels correlate with an invasive 
phenotype, we compared highly invasive breast cancer 
cell lines with those that were weakly invasive or 
non-invasive (Figure 1A). Invasive breast cancer cell 
lines (MDA-MB-231, MDA-MB-468) expressed higher 
levels of pYB-1S102/total YB-1 than non-invasive cell lines 
(T47D, MCF7) (Figure 1A).
Next, we sought to determine the role of YB-1 in the 
acquisition of metastatic features. We stably infected three 
breast cancer cell lines (MCF7, MDA-MB-468, and MDA-
MB-231) with retrovirus expressing YB-1 (pLPCX-YB-1) 
or with control empty vector (pLPCX). We verified forced 
expression of YB-1 at both RNA (Figure S1A) and protein 
(Figure 1B) levels. Forced expression of YB-1 in MCF7 
cells (MCF7YB-1) increased the number of cell colonies 
compared with control cells (P = 0.004; Figure 1C). 
Additionally, YB-1 overexpression induced EMT features, 
including transcriptional upregulation of SNAI1 mRNA 
(Snail1, an E-cadherin repressor) and downregulation of 
CDH1 mRNA (E-cadherin) (Figure S1B).
Because cell migration and invasion are important 
characteristics acquired during the EMT process [35], 
we performed migration wound-healing experiments 
in serum-free medium to exclude interference from 
the proliferative action of YB-1. Consistent with the 
changes in gene expression, MDA-MB-468YB-1 and 
MDA-MB-231YB-1 cells showed increased cell motility 
(P = 0.001 and P = 0.008; Figure 1D). MCF7 cells did 
not display any appreciable migration for the duration of 
this assay and were therefore excluded (data not shown). 
Consistent with a role for YB-1 in promoting EMT-like 
features, MDA-MB-468YB-1 and MDA-MB-231YB-1 cells 
displayed ~4.5-fold increased invasion rates compared 
with control cells (P = 0.001; Figure 1E). In MCF7 cells, 
increased YB-1 expression levels significantly activated 
cell invasion (12-fold, P = 0.025). These results indicate 
that YB-1 increased the motility and invasive capacity 
of breast cancer cells, implying a role for YB-1 in breast 
cancer progression and metastasis.
Loss of YB-1 promotes an epithelial-like 
phenotype
Given the proposed functional involvement 
of YB-1 in the EMT [30, 32, 33], we asked whether 
YB-1 knockdown would decrease the mesenchymal 
characteristics of MDA-MB-231 cells. This cell line 
has undergone EMT and has considerable levels of total 
and pYB-1S102 (Figure 1A). We infected MDA-MB-231 
cells with lentiviral vectors (short hairpin RNA [shRNA] 
control or two shRNAs targeting YB-1). After 4 days of 
antibiotic resistance selection, cells formed clusters with 
a more cuboidal epithelial-like morphology (Figure 2A). 
MDA-MB-231 cells transfected twice with YB-1 two 
different short interfering RNAs (siRNAs, targeting YB-1) 
showed similar morphological changes (Figure S2A and 
S2B). Quantitative real-time PCR (qRT-PCR) and Western 
blot confirmed the inhibition of YB-1 (Figure 2B and 2C). 
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Figure 1: YB-1 promotes migration and invasion in breast cancer cells. a. Western blot analysis of breast cancer cells lines 
showing their phosphoYB-1 (pYB-1S102) and total YB-1 protein levels. b. Effects of forced expression of YB-1 in breast cancer cells. Cells 
were stably transfected with plasmids (5 μg) expressing YB-1 (pLPCX-YB-1) or an empty control plasmid (pLPCX), as indicated. The 
levels of the mesenchymal marker vimentin, pYB1S102, and total YB-1 are shown. c. Semi-fluid basement membrane assay of MCF7 and 
MCF7YB-1 cells. Colonies formed after incubation for 10 days. *P < 0.05 versus control by Student’s t test. Representative photomicrographs 
of colonies formed by the cells growing in Matrigel. Scale bar, 160 μm. d. Cell migration was studied with a scratch-wound assay in MDA-
MB-468 and MDA-MB-231 cells expressing control and YB-1 vectors (mean ± SEM; **P < 0.001 by Tukey’s post-hoc test.
(Continued )
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These changes in cellular appearance were mirrored by 
the concurrently decreased levels of the mesenchymal 
marker vimentin and the EMT inducers Snail1 and 
Twist (Figure 2C) and reduced invasiveness (P = 0.001; 
Figure 2D). In summary, YB-1 knockdown is sufficient 
to reverse the phenotype of cancer cells and make them 
regress and adopt a more epithelial phenotype.
IL-6 induces YB-1 expression and activation
IL-6 induces and maintains the EMT through feed-
forward loops in a variety of carcinomas, including breast 
[20, 36]. The main biological effects of IL-6 are mediated 
by activation of the STAT3 pathway. STAT3 needs to 
be phosphorylated at tyrosine residue 705 (pSTAT3Y705) 
to allow the formation of dimers that translocate to 
the nucleus to regulate gene transcription [37]. Many 
cancer cell lines show nuclear STAT3 translocation with 
subsequent transcriptional activation of programs such as 
the EMT. We analyzed a large number of breast cancer 
cell lines with Gene Expression-Based Outcome for 
Breast Cancer Online (GOBO) [38], finding that TNBC 
and HER2-positive breast cancer cell lines express higher 
levels of YBX1 and STAT3 (Figure S3A). TNBC cell 
lines had abundant levels of pSTAT3Y705 protein based on 
immunoblotting (Figure S3B).
To study the effect of IL-6 on YB-1, we stimulated 
MCF7 cells with recombinant human IL-6 (25 ng/mL) 
to induce an EMT-like phenotype [20]. MCF7 cells had 
low levels of pYB-1S102 (see Figure 1A) and respond to 
IL-6 via the IL-6 receptor components alpha (gp80) and 
gp130 [27]. Control MCF7 cells displayed a characteristic 
cobblestone and epithelial morphology, whereas cells 
treated with IL-6 for 10 days displayed a more fibroblastic 
morphology with scattered distribution, suggesting a 
partial activation of the EMT program (Figure 3A). In 
accordance with these changes, IL-6–stimulated cells 
displayed increased YBX1 and SNAI1 mRNA levels 
and decreased CDH1 mRNA levels (Figure S3C). IL-6 
treatment also increased pYB-1S102 levels as well as 
activated STAT3 (Figure 3B) in a similar fashion to 
epidermal growth factor (EGF) treatment (Figure 3B). 
Upregulation of pYB1S102 by IL-6 was in a dose-dependent 
manner (Figure S3D).
The specificity of YB-1 phosphorylation by IL-6 
was checked by siRNA-mediated knockdown of STAT3 
in MDA-MB-468 cells. This cell line produces IL-6 
and can respond to autocrine IL-6 signaling. Cells with 
silenced STAT3 had reduced pYB-1S102 levels (Figure 3C). 
Subsequent YB-1 activation partially required STAT3 
phosphorylation by IL-6. Together, this suggests that 
YB-1 is activated (pYB-1S102) by the STAT3 pathway 
(via various upstream pathways), which may represent a 
common feature among breast cancer cells.
Phosphorylation of YB-1 can lead to nuclear 
translocation in cancer cells [39]. In basal conditions, 
pYB-1S102 localized mainly to the cytoplasm. After IL-6 
treatment, pYB-1S102 translocated to the nucleus within 
Figure 1: (Continued ) e. Matrigel invasion assay in MCF7, MDA-MB-468, and MDA-MB-231 cells stably expressing the two different 
plasmids described above. Cells were harvested after 16 h and 5 × 104 cells were seeded onto the Transwell invasion chamber for 24 h. 
Cells that crossed the Matrigel-coated filter were fixed, stained, and counted. Representative bright-field images of the bottom surface are 
shown. Six random microscopic fields were counted for each group. Results are presented as the fold change over each parental cell line 
(mean ± SEM; *P < 0.05, **P < 0.01 by Student’s t test).
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Figure 2: YB-1 knockdown reverses EMT features toward a more epithelial-like phenotype in MDA-MB-231 
cells. a. Morphologic changes in MDA-MB-231 cells after infection with shRNA-YB-1#1 and #2 or empty vector. Arrows indicate clusters 
of cells with epithelial-like morphology. b. qRT-PCR determination of YBX1 mRNA. The transcript levels of cells transfected with control 
shRNA were set as 1. Means ± SEM are shown for three independent experiments. *P < 0.05, **P < 0.01 compared with cells transfected with 
control shRNA by Tukey’s test. c. Western blot analysis was performed in shRNA-infected MDA-MB-231 cells. d. Transwell invasion assay 
showed a diminished invasive capacity after YB-1 knockdown. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01 by Tukey’s test.
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Figure 3: IL-6 induces YB-1 phosphorylation in MCF7 cells. a. Phase contrast photomicrographs of cells treated with IL-6 
(50 ng/mL, 10 days) cultured in regular plates (top) or collagen type I-coated plates (below). MCF7 cells undergoing EMT-like morphologic 
changes. Scale bar, 161 μm. b. Western blot assessing pYB-1S102 expression under IL-6 stimulus in breast cancer cell lines. Phospho-
STAT3 (pSTAT3Y705) indicates STAT3 activation in the IL-6 signaling pathway. c. Western blot of MDA-MB-468 and MDA-MB-231 
cells transfected for 96 h with STAT3 siRNAs. Levels of pSTAT3, pYB-1S102, and total YB-1 are shown. d. Subcellular localization of 
pYB-1S102 after IL-6 (25 ng/mL) treatment in MCF7 cells. N, nuclear, C, cytoplasm. e. YBX1 mRNA levels assessed by qRT-PCR in 
IL-6–overexpressing cells. f. Western blot analysis of breast cancer cells overexpressing IL-6.
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30 min, maintaining its localization until at least 4 h. 
However, some pYB-1S102 remained in the cytoplasm of 
MCF7 cells (Figure 3D). YB-1 phosphorylation by IL-6 
leads to changes in intracellular localization. On the other 
hand, forced IL-6 expression increased YBX1 mRNA 
(Figure 3E) and total YB-1/pYB-1S102 protein (Figure 3F) 
levels.
Induction of EMT-like characteristics 
requires YB-1
To gain insight into the relationship between 
YB-1– and IL-6–induced EMT-like features, we 
investigated the impact of YB-1 depletion on cellular 
migration and invasion in MDA-MB-231 cells with 
or without the presence of IL-6. Cells transfected with 
either siRNAs targeting YB-1 (short-term silencing; 96 h; 
Figure S4A) or with YB-1 shRNAs (long-term silencing; 
Figure 4A) had significantly lower migratory (Figure 4A 
and S4A; **P < 0.001) and invasive (Figure 4B; *P < 0.05, 
**P < 0.01) rates than control cells. Depletion of YB-1 
blocked the increased migratory and invasive capacities 
caused by IL-6 stimulation (Figure 4B; *P < 0.05, 
**P < 0.01), suggesting that IL-6–induced migratory 
and invasive features require YB-1 signaling. Moreover, 
IL-6–stimulated cell lines displayed increased invasiveness 
(Figure S3E), suggesting a relationship between increased 
cell invasion and increased YB-1 expression.
Next, we silenced YB-1 in MCF7 cells treated with 
IL-6 or with TGFβ (a well-known regulator of EMT). 
After 13 days of treatment, control cells displayed EMT-
like features, whereas YB-1–knockdown cells failed 
to undergo EMT-associated morphological changes 
(Figure 4C). Moreover, we observed increased cell death 
upon IL-6 stimulation in cells where YB-1 had previously 
been silenced. This suggests that YB-1 may be a critical 
mediator of EMT-like features induced by a variety of 
upstream pathways, including IL-6 and TGFβ.
Forced expression of YB-1 increases IL-6 levels
We wanted to determine whether YB-1 could activate 
IL-6 expression in breast cancer cells. In all three cell 
lines, changes in YB-1 levels increased IL6 mRNA levels 
(Figure 5A; *P < 0.05, **P < 0.01). Cytokine expression is 
usually transient and IL6 mRNA has a particularly unstable 
nature due to the presence of Au-rich elements (AREs) in 
its 3′UTR [40]. YB-1 has been described as a structural 
component of messenger ribonucleoprotein particles 
(mRNPs) [41, 42] that can act as an ARE RNA-binding 
protein, meaning that it can regulate the stability and/
or translation of target mRNAs. We performed an RNA-
binding protein immunoprecipitation (RIP) assay to analyze 
whether YB-1 could bind and stabilize IL6 mRNA. As a 
control, we used SNAI1 because YB-1 is known to bind and 
stabilize its mRNA (Figure S5A). We observed a striking 
increase in total IL6 RNA levels bound to YB-1 protein in 
MDA-MB-231YB-1 cells (Figure 5B), suggesting that YB-1 
may induce IL6 mRNA stability via direct binding.
Overexpression of YB-1 increased pSTAT3Y705 in 
the cell lines tested (Figure 5C). Levels of pSTAT3Y705 
can be indicative of IL-6 presence in the supernatant. To 
confirm this result, serum-free supernatants were tested 
by IL-6 ELISA. We confirmed that cells with forced YB-1 
expression displayed 2–3-fold increased IL-6 levels in 
the supernatant (Figure 5D). In contrast, YB-1 depletion 
reduced IL-6 levels in the supernatant (Figure 5D and S5B).
These results indicate that YB-1 and IL-6 interplay 
at another novel level, so that YB-1 is not only regulated 
by IL-6, but IL-6 is also reciprocally regulated by 
YB-1. Thus, one mechanism used by YB-1 to induce 
mesenchymal characteristics could be modulation of IL-6 
levels in the medium.
IL-6 blockage abrogates YB-1 activation, cell 
migration, and invasion
To determine the contribution of IL-6 to YB-1–
induced migration and invasion, we blocked IL-6 
signaling. The presence of an IL-6 monoclonal antibody 
that neutralized secreted IL-6 reduced the levels of 
both pYB-1S102 and pSTAT3Y705 (Figure 6A). Anti–IL-6 
treatment blocked the migration and invasion induced by 
YB-1 overexpression (Figure 6B and 6C).
We explored the ability of inhibitors targeting 
STAT3 (S3I-201) and MEK (PD98059) to inhibit IL-6 
signaling. These are key IL-6–regulated proteins that 
can also activate YB-1. Both STAT3 and MEK inhibition 
blocked IL-6 induction of morphological changes 
(Figure 6D) and the combination of the two inhibitors 
blocked IL-6 phosphorylation of YB-1 (Figure 6E). 
Critically, inhibition of either STAT3 or MEK was 
sufficient to maintain the epithelial morphology of MCF7 
cells following IL-6 treatment.
High levels of YB-1 and Stat3S727 correlate in 
both breast cancer cell lines and human breast 
tumors
As discussed above, the IL-6 signaling pathway 
primarily involves activation of STAT3 by Tyr705 
phosphorylation. However, STAT3 can also be 
phosphorylated at Ser727. The importance of Ser727 is 
still controversial because the pathways subsequently 
activated are different from those activated by Tyr705 
[43]. In different cell models, the link between YB-1 and 
pSTAT3S727 affects cell survival [44, 45]. Therefore, we 
explored the levels of STAT3 phosphorylation at Ser727. 
Cells overexpressing YB-1 or IL-6 had increased levels of 
pSTAT3S727 (Figures 7A, S6A and S6B, S6C). Consistent 
with these results, high endogenous levels of YB-1 also 
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Figure 4: YB-1 is involved in the IL-6–induced metastatic phenotype. a. Wound healing migration assays in shControl (pLKO-
shControl)- and shYB-1 (pLKO-shYB-1)-infected MDA-MB-231 cells (left) without or with IL-6 treatment. Representative photographs 
of three independent experiments (right). b. Matrigel invasion assays of MCF7 and MDA-MB-231 cells transfected with 30 nM of siRNA 
control or two different siRNAs targeting YB-1. After 72 h, cells were seeded in Matrigel-coated Transwell invasion plates in the absence 




correlated with elevated pSTAT3S727 levels in breast cancer 
cell lines (Figure S6D).
Next, we sought to analyze the correlation between 
YB-1 levels and metastasis in high-grade breast cancer 
tissues. Normal breast tissue expressed low levels of 
YB-1 and pSTAT3S727 (Figure 7C). In contrast, 62.5% 
of high-grade breast carcinomas presented moderate-to-
elevated levels of YB-1 and 76.6% had elevated levels 
of pSTAT3S727 (Figure S6E). Of samples with elevated 
pSTAT3S727 levels, 66.3% were highly positive for YB-1 
(Figure 7C and 7D). Of the tumors with metastasis, 79.4% 
exhibited moderate-to-high levels of positive staining 
for YB-1 (Figure 7D; P = 0.013). In high-grade breast 
tumors, YB-1 correlated with metastasis and tended to be 
associated with high levels of pSTAT3S727.
DISCUSSION
Despite significant improvements in the diagnosis 
and treatment of breast cancer, recurrence and metastasis 
are still common and major causes of death. In the present 
study, we have provided new insights into the interaction 
between YB-1 and IL-6, two critical proteins in breast 
metastasis that can be pharmacologically targeted.
YB-1 is a powerful oncoprotein implicated in many 
cellular processes, including multidrug resistance [46] 
and metastasis [29]. Consistent with our data, YB-1 has 
been associated with aggressive types of breast cancer, 
which are mainly ER negative [10] and display a more 
invasive/metastatic phenotype. In agreement with this 
metastatic phenotype, overexpression of YB-1 induced 
EMT-like features in the breast cancer cells studied, such 
as increased cell migration and invasion. Forced YB-1 
expression increased the levels of the mesenchymal 
marker SNAI1 and downregulated CDH1 (E-cadherin) 
mRNA levels. An inverse relationship between YB-1 
and E-cadherin levels has been reported in many 
cancer cell lines and breast tumors [29, 32, 33, 47]. 
Upregulated levels of YB-1 can induce a cadherin switch, 
in which E-cadherin is replaced by N-cadherin [33, 48]. 
Nevertheless, it remains unclear whether YB-1 directly 
represses E-cadherin (transcriptionally or translationally) 
or acts indirectly by activating E-cadherin repressors such 
as Twist or Snail. In our setting, YB-1 knockdown in 
MDA-MB-231 cells reduced Snail1, Twist, and vimentin 
levels with a concomitant reduction in migration and 
invasion rates. However, we did not observe significant 
changes in E-cadherin at the protein level (data not shown) 
after YB-1 modification. Nevertheless, YB-1–depleted 
MDA-MB-231 cells adopted a more epithelial-like 
morphology, similar to other studies of MDA-MB-231 
cells in which Snail1 was depleted [49] or E-cadherin was 
ectopically expressed [50–52]. Together, our results are 
consistent with prior findings [30–33, 53] showing that 
YB-1 promotes the acquisition and maintenance of an 
EMT-like phenotype.
IL-6 is a pleiotropic cytokine that modulates the 
phenotype of many cancer types by binding to IL-6 
receptors and activating downstream pathways, thereby 
promoting tumor initiation, development, and metastasis 
[54]. We found that IL-6 increased pYB-1S102 in a similar 
manner to other growth factors such as EGF [30] or 
Figure 4: (Continued ) c. Phase contrast images show morphological changes in MCF7 cells expressing shControl or shYB-1 with or 
without IL-6 or TGFβ treatment for 13 days in collagen-coated plates. NT, non-treated.
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cytokines such as TGFβ or IL-2 [55]. Once YB-1 is 
phosphorylated, it mainly translocates to the nucleus 
where it promotes the transcription of genes involved in 
cell migration, invasion, drug resistance, and survival. 
Under stress conditions, YB-1 promotes cap-independent 
translation of pro-survival and growth genes [56], as 
well as transcriptional activation of drug resistance 
genes (MDR1) or drug transporters (ABCC1 and MVP1). 
Our observations indicate that YB-1 may be involved in 
the survival of IL-6– or TGFβ-stimulated cells. Most of 
the cells depleted of YB-1 stop growing and die in the 
presence of one of these cytokines. We hypothesized that 
YB-1 could be involved in the signaling pathways of both 
cytokines and that its absence could be crucial for survival. 
One reason may be the positive association between YB-1 
and the levels of activated STAT3, which is a pro-survival 
Figure 5: YB-1 drives IL-6 expression in breast cancer cell lines. a. qRT-PCR analysis of IL6 mRNA levels after forced YB-1 
expression in MCF-7, MDA-MB-468, and MDA-MB-231 cells and in YB-1–depleted MDA-MB-231 cells compared with control cells. 
The indicated means are significantly different. *P < 0.05, **P < 0.01 by Tukey’s test. b. RIP in MDA-MB-231YB-1 cells compared with 
control cells. c. On the left, Western blot analysis of cells transfected with YB-1 vector or control empty vector and, on the right, MDA-
MB-231 cells transfected with shRNA of YB-1. d. IL-6 ELISA analysis of serum-free culture supernatants.
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Figure 6: Involvement of IL-6 in YB-1–promoted migration and invasion. Cells were incubated with 2 μg/mL anti-mouse as 
a negative control or 2 μg/mL anti–IL-6 antibody. a. Western blot analysis, b. cell migration, and c. cell invasion assays of control and 
MDA-MB-231YB-1 cells pretreated with anti-mouse or anti–IL-6 antibody for 20 h. Values are the mean ± SEM of the fold change over 
MDA-MB-231 non-treated cells. *P < 0.05, **P < 0.001 by Tukey’s tests. d. Treatment of MCF7 cells with inhibitors of MEK (50 μM 
PD98059) and/or STAT-3 (100 μM S3I-201) significantly inhibited IL-6–induced EMT-like phenotype. Phase contrast photomicrographs. 
Scale bar, 161 μm. NT, non-treated.
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Figure 7: YB-1 and pSTAT3S727 are present in most human invasive/aggressive breast cancer types. a. Western blot 
analysis of MCF7 cells transfected with increasing amounts of pLPCX-YB-1. b. Dose-dependent correlation between pYB-1S102 and 
pSTAT3S727 activation in breast cancer cells. Experiments were repeated twice, and bands were quantified using ImageJ software. Regression 
analysis was then conducted to determinate the correlation between pYB-1S102 and pSTAT3S727. c. Immunohistochemical staining for YB-1 
and pSTAT3S727 in a tissue microarray of 138 high-grade breast carcinomas and normal breast samples. Shown is a representative sample 
of normal breast (left) and breast carcinoma samples with low and high expression of YB-1. Scale bar, 100 μm. d. Relationship between 
YB-1 amplification and clinicopathological features in high-grade breast cancer.
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factor in several cancer cells. Interestingly, in an in 
vivo model of renal cancer, inhibition of YB-1 caused 
a concomitant decrease in STAT3 levels and increased 
sensitivity to cytokine IFN-α treatment. This combination 
had antitumor effects, indicating the pro-survival function 
of YB-1/STAT3 [45].
Our findings showed that YB-1 overexpression 
promoted the development of a metastatic phenotype that 
seems to be dependent upon IL-6 activity. It has been 
suggested that YB-1 can mediate part of these metastatic 
effects via the release of extracellular proteinases such 
as metalloproteinase 2 (MMP2), MMP13, MT1-MMP 
[29], and gelatinase A [57]. Interestingly, MMP release 
can be induced by IL-6 and some MMPs can regulate 
IL-6 expression. Hence, it is feasible that YB-1 would 
promote invasive effects through increased MMP 
secretion via IL-6 [58] or, alternatively, through a 
direct induction of MMPs that subsequently increase 
IL-6 expression [59]. YB-1 overexpression increased 
IL6 mRNA and IL-6 secretion in the three cell lines 
tested. In view of these results and those of the RIP 
assay, it is feasible that YB-1 would be involved in the 
transcriptional regulation of IL-6, maybe as a factor 
located near the promoter region [60].
The idea that YB-1 is a transcription factor that 
activates IL-6 promoter activity is in agreement with a 
ChIP sequencing study in trastuzumab-resistant breast 
cancer cells that identified IL-6 and IL-6R as YB-1 
transcriptional targets [61]. However, our YB-1/RNA 
co-immunoprecipitation assay indicated a direct binding 
with IL6 at the RNA level, suggesting that YB-1 can 
be loaded on partially synthesized primary IL6 RNAs 
to control aspects of RNA metabolism. Several studies 
have shown the ability of YB-1 to stabilize short-lived 
mRNA species such as IL-2 [62], GM-CSF [42], VEGF, 
and TGFβ [63], suggesting a link between YB-1 and 
post-transcriptional regulation of cytokines. Based on 
our RIP assay results, YB-1 can bind IL6 RNA and may 
stabilize it, which is in accordance with a previous study 
[64] that showed that YB-1 regulates IL6 mRNA stability 
in immune cells. Breast cancer cells overexpressing 
YB-1 had increased IL-6 production. This finding 
agrees with the evidence indicating that cancer cells 
secrete cytokines and chemokines to promote tumor 
progression via feed-forward loops in autocrine and 
paracrine manners. Autocrine loops are highly relevant in 
cancer progression and, in particular, the importance of 
IL-6 autocrine signaling in breast cancers is well known 
[18, 65]. In the present study, we found that IL-6 both 
induced and required YB-1 in order to activate EMT-
like characteristics, including increased motility. On the 
other hand, the induction of an EMT phenotype by YB-1 
required IL-6 signaling. Both proteins seem to create 
a positive feed-forward loop between each other that 
could explain the frequent co-expression of YB-1 and 
STAT3 [66].
IL-6 exerts most of its target gene expression 
functions via STAT3. The transcriptional activity of 
STAT3 is generally controlled by Tyr705 phosphorylation. 
Ser727 phosphorylation represents an additional level of 
regulation that increases STAT3 transcriptional activity 
[67], but the mechanism remains unclear. Although 
our results were not statistically significant, we found a 
tendency for an association between high levels of YB-1 
and pSTAT3S727 in high-grade breast tumors. As pointed 
out in other tumor types, high levels of YB-1 positively 
correlate with metastasis [13, 29].
In conclusion, we have shown that (i) YB-1 
overexpression promotes EMT features, cell migration, 
and invasion in breast cancer cell lines; (ii) YB-1 
knockdown partially reverts the EMT phenotype of 
MDA-MB-231 cells; (iii) YB-1 regulates the IL-6/STAT3 
pathway by inducing IL-6 de novo synthesis and activity; 
(iv) IL-6 is required for YB-1–induced acquisition of 
EMT-like features; (v) IL-6 can activate YBX1 mRNA 
expression and YB-1 phosphorylation/activation; and (vi) 
induction of EMT by IL-6 requires YB-1. Elucidating 
the signaling pathways that govern the interdependence 
between IL-6 and YB-1 may uncover novel therapeutic 
approaches. These therapies might be particularly effective 
in patients with aggressive breast tumors that express high 
levels of YB-1 and pSTAT3.
MATERIALS AND METHODS
Cell culture
Breast cancer cell lines were purchased from the 
American Type Culture Collection (ATCC, Manassas, 
VA). MCF7 cells were maintained in RPMI 1640 medium 
while MDA-MB-231 and MDA-MB-468 cells were 
maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) (Invitrogen, El Prat del Llobregat, Spain). Both 
media were supplemented with 10% heat-inactivated 
FBS (Invitrogen) and 1% antibiotic/antimycotic solution 
(10,000 U/mL penicillin G, 10 mg/mL streptomycin, and 
25 μg/mL amphotericin B).
Reagents and chemicals
Recombinant human IL-6 and EGF were purchased 
from Sigma-Aldrich (H7416 and E9644), reconstituted in 
phosphate-buffered saline, and used at final concentrations 
of 25 and 50 ng/mL, respectively. TGFβ was purchased 
from Sigma-Aldrich and used at a final concentration of 
5 ng/mL. The MEK1/2 inhibitor PD98059 and STAT3 
inhibitor S3I-201 were purchased from Calbiochem, 
dissolved in dimethyl sulfoxide (DMSO), and used at final 
concentrations of 50 μM and 100 μM, respectively. Cells 
were preincubated with the inhibitors for 1 h at 37°C and 
then incubated in the absence or presence of IL-6. The 
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experiments ran for 4 days and media with inhibitor was 
changed every 2 days. BIX15 was purchased from Vibrant 
Pharma (Brantford, ON), dissolved in DMSO, and used at 
a final concentration of 5 μM. Control cells were treated 
with the same amount of DMSO (Vehicle).
Modulation of expression using retroviral and 
lentiviral infection
Five micrograms of plasmids containing full-
length cDNA of human YBX1 in an pLPCX retroviral 
vector (pLPCX-YB1), cDNA of human IL6 in a 
pLNCX (pLNCX-IL-6) vector, and an empty pLPCX 
retroviral vector (pLPCX) were used to generate viral 
supernatant in Phoenix packaging cells transfected with 
jetPEI® (Polyplus, Illkirch, France) according to the 
manufacturer’s protocol. Viral production and infection 
were performed at 37°C. All of these plasmids were 
sequenced twice from both sides to ensure expression of 
the correct coding sequence.
Regarding lentiviral shRNA, pLKO.1-puro-
YB-1#1 and human YBX1#2 targeted 5′-CAGGCGAAGG 
TTCCCACCTT A-3′ and 5′-CAAGAAGGTC 
ATCGCAACGA A-3′, respectively. As a control, we used 
pLKO-shLUC, which targets human LUC. Production of 
lentiviruses and retroviruses and their infection of target 
cells were performed as previously described [68]. Infected 
MDA-MB-231 or MCF7 cells were selected with 2 μg/mL 
puromycin for 3–4 days; MDA-MB-468 cells were selected 
with 1 μg/mL puromycin for 3–4 days; and pLNCX-IL-6 
cells were selected with 400 μg/mL G418 for 7 days.
Knockdown analysis using siRNA transfection
Cells were reverse-transfected in 6-well plates 
with 10 nM siYB-1 or 50 nM siSTAT3 with RNAiMAX 
(Invitrogen) reagent according to the manufacturer’s 
protocol. Double-stranded RNA purchased from Qiagen 
targeting YBX1 (siYB-1#1: Hs_YBX1_1 FlexiTube 
siRNA SI03019191; siYB-1#2: Hs_YBX1_3 FlexiTube 
siRNA SI04172007), STAT3 siSTAT3#1 (Dharmacon 
Research, Inc.), siSTAT3#2 (Qiagen, Hilden, Germany), 
or non-silencing control (FlexiTube Control siRNA 
SI03650325) were used. Cells were assessed after 72 h of 
siRNA transfection.
Protein extraction and immunoblotting
Total cellular extraction
Total protein extracts were generated using RIPA 
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton 
X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM EDTA) 
supplemented with PhosSTOP and Complete Phosphatase/
Protease Inhibitor Cocktails (Roche Diagnostics GmbH, 
Mannheim, Germany). Protein extracts (20–25 μg per 
sample) were loaded onto gels and immunodetection of 
proteins was performed using ECL™ Western Blotting 
Detection Reagents (GE Healthcare, Buckinghamshire UK).
Extraction of cytoplasmic and nuclear proteins
Cytoplasmic and nuclear proteins extracts were 
prepared with NE-PER® Nuclear and Cytoplasmic 
Extraction Reagents (Thermo Scientific, Rockford, IL) 
according to the manufacturer’s description. The 
following primary antibodies were used: anti-YB1 
(Millipore), 1:20000; anti-pYB1 S102 (Cell Signaling), 
1:1000; anti-actin (Sigma, St. Louis, MO), 1:5000; anti-
STAT3 (Cell Signaling), 1:1000; anti-STAT3 S727 (Cell 
Signaling), 1:1000; anti-STAT3Y705 (Cell Signaling), 
1:1000; anti-Snail (Cell Signaling), 1:1000; anti-Twist 
(Santa Cruz Biotechnology), 1:1000; anti-vimentin 
(Santa Cruz Biotechnology), 1:1000; anti-GAPDH (Santa 
Cruz Biotechnology), 1:1000; anti-vinculin (Sigma), 
1:1000; anti-LaminAC (Sigma), 1:10.000. Secondary 
antibodies (Calbiochem, La Jolla, CA) were used at 
1:15000. Signals were scanned and quantified using 
ImageJ software.
Quantitative real-time PCR
Total RNA was extracted from cells using RNAzol® 
RT (MRC Inc., Cincinnati, OH) and 1 μg total RNA was 
used to synthesize cDNA using SuperScript® III Reverse 
Transcriptase (Invitrogen, Life Technologies). qRT-
PCR was performed on a Veriti 96-well Thermal Cycler 
(Applied Biosystems). TaqMan® Gene Expression Assays 
were purchased from Invitrogen (YBX1: Hs02742755_g1; 
CDH1: Hs00170423_m1; IL6:Hs00985639_m1; SNAI1: 
Hs00195591_m1; and ACTB: Hs99999903_m1). To 
quantify changes in gene expression, the comparative 
Ct (ΔΔCT method) was used to calculate the relative fold 
change normalized to actin.
RNA-binding protein immunoprecipitation
MDA-MB-231 cells were transfected with empty 
vector or pLPCX-YB-1 vector as described above. RNA-
binding protein assay was performed with Magna RIP™ 
(Millipore, Billerica, MA) following the manufacturer’s 
protocol. Mock control was done using a rabbit IgG 
and sample RNA-binding proteins were obtained using 
YB-1 IgG (Millipore). RNA-protein complexes were 
eluted at 95°C. Eluates were treated with proteinase K 
and RNA was ethanol-precipitated after extraction 
with phenol:chloroform:isoamyl. RNA quality was 
assessed using a NanoDrop. After treatment with DNaseI 
(Fermentas,Thermo Scientific), mRNA was subjected to 
cDNA synthesis and qRT-PCR was performed as described 
above. Fold enrichment was calculated as 2–[(Ct IP) – (Ct mock)]. 
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This normalization is also referred to as “signal over 
background” or “relative to the no-antibody control”. 
With this method, the RNA-IP signals are divided by the 
no-antibody signals, representing the RNA-IP signal as the 
fold increase in signal relative to the background signal.
IL-6 ELISA
ELISA was performed with an IL-6 ELISA kit 
(Invitrogen). Breast cancer cell lines with or without 
YB-1 were harvested at a concentration of 1.5 × 106 in 
p60 plates, washed twice in medium (DMEM), and 
incubated in serum-free medium. Supernatant samples 
were harvested at 16 h and IL-6 levels were analyzed 
by following the manufacturer’s instructions. Briefly, 
supernatant samples were added to wells in triplicate 
and incubated for 1 h at RT. They were then washed 
three times and incubated in anti–IL6-HRP conjugate 
solution for 1 h at RT, washed as described, and incubated 
with chromogen for 15 min at RT. The wells with the 
chromogen substrate were read at a wavelength of 490 nm 
with a microplate reader. Quantitative data are presented 
as average concentrations in pg/mL.
Three-dimensional morphogenesis assay  
(semi-fluid basement membrane)
Growth factor-reduced Matrigel basement 
membrane (BD Biosciences, San Jose, CA) was added 
at a concentration of 40 μL per well to a 96-well plate 
and solidified by incubation at 37°C for 30 min. MCF7 
cells stably transfected with empty vector (pLPCX) or 
YB-1–expressing vector (pLPCX-YB-1) in a single-cell 
suspension were added to the Matrigel wells in their 
respective media at 2 × 103 cells/well. Colony growth was 
assessed in fields photographed 10 days after seeding.
Cell migration (wound healing) assay
Cells were plated in 24-well plates in triplicate; 
16 h before wounding of the confluent monolayer by 
scratching, the medium was removed and replaced by 
serum-free medium. Photomicrographs were taken and 
wound closure was measured using ImageJ software.
Cell invasion assay
Invasion assays were carried out in modified 
Boyden chambers with Transwell inserts of 8-μm pore 
filters for 24-well plates (Millipore). Transwell inserts 
were coated with 70 μL diluted Matrigel basement 
membrane (BD Biosciences) for 30 min at 37°C. The 
cells were detached with trypsin and washed twice with 
serum-containing medium. Next, 200 μL of cells (2.5 × 
105 cells/mL) were resuspended and seeded in the upper 
chamber in serum-free medium in the presence or absence 
of IL-6 (20 ng/mL). Complete medium was placed in the 
lower compartment as a chemoattractant. Cells were also 
transfected with the appropriate siRNA for 48 h and then 
collected and resuspended in serum-free medium in the 
presence or absence of IL-6 (20 ng/mL). These cells were 
seeded in the upper chamber for 24 h at 37°C in a 5% 
CO2 humidified incubator. Non-invading cells on the top 
of the matrix were removed by rubbing the matrix with a 
moistened cotton swab. Cells that migrated through the 
permeable membrane were fixed in 3.7% formaldehyde, 
permeabilized with methanol, washed twice with 
phosphate-buffered saline, and stained with 0.2% crystal 
violet. Six random fields were photographed and cells 
were counted using ImageJ software.
Immunohistochemical staining
A tissue microarray containing 138 high-grade 
breast tumor specimens was stained as described 
previously [69].
Statistical analysis
Statistical analysis of the tissue microarray 
correlations between STAT3 phosphorylated at serine 
727 (pSTAT3S727) and YB-1 staining in the clinical 
samples were determined using the Spearman’s test. For 
our analysis, YB-1 was scored as 0 (negative) or 1(low 
levels), 2 (moderately positive), and 3 (highly positive). 
To determine the association between the presence/
absence of YB-1 and the presence of pSTAT3S727, we used 
the chi-square test. Results were considered statistically 
significant at a P value of < 0.05.
Differences in continuous variables between groups 
were analyzed for statistical significance with one-way 
analysis of variance (ANOVA) followed by Tukey’s post-
hoc test using PASW 18 software (Chicago, IL). When 
the variance was not homogenous, we used the non-
parametric Mann-Whitney U test or the Kruskal-Wallis 
test. Results are expressed as the mean ± SEM of at least 
three independent experiments and differences were 
considered significant at P < 0.05. In invasion assays, 
statistical analysis was performed by applying a two-
sample t test assuming equal variance, and P values were 
calculated based on a two-tailed test.
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